Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q4Scopus Q2
- 저널
- GUT AND LIVER7(4) · pp.406 · 2013
- 피인용
- Web of Science 17KCI 7
- JCR IF
- JCR 2012 1.314
- ISSN
- 1976-2283
저자
- 문지윤제1저자부산대학교, 부산대학교병원, 대학병원, KO
- 김광하교신저자부산대학교, 의과대학, 의과학과, KO
- You, Hyun Seok부산광역시의료원, Dept Internal Med, KO
- 이봉은부산대학교, 의과대학, 의학과, KO
- 류동엽부산대학교, 부산대학교병원, 대학병원, Dept Internal Med, KO
- 정재훈부산대학교, 부산대학교병원, 대학병원, KO
- 정정임부산대학교, 부산대학교병원, 대학병원, KO
- Jeong, Jae Hoon좋은삼선병원, Dept Internal Med, KO
- Song, Chul Soo좋은삼선병원, Dept Internal Med, KO
- 송근암부산대학교, 의과대학, 의학과, KO
초록
Background/Aims: Several rescue therapies have been recommended to eradicate Helicobacter pylori infection in patients with a failure of first-line eradication therapy, but they still fail in more than 20% of cases. The aim of this study was to evaluate the efficacy and safety of levofloxacin, metronidazole, and lansoprazole (LML) triple therapy relative to quadruple therapy as a second-line treatment. Methods: In total, 113 patients who failed first-line triple therapy for H. pylori infection were randomly assigned to two groups: LML for 7 days and tetracycline, bismuth subcitrate, metronidazole and lansoprazole (quadruple) for 7 days. Results: According to intention-to-treat analysis, the infection was eradicated in 38 of 56 patients (67.9%) in the LML group and 48 of 57(84.2%) in the quadruple group (p=0.042). Per-protocol analysis showed successful eradication in 38 of 52 patients (73.1%) from the LML group and 48 of 52 (92.3%) from the quadruple group (p=0.010). There were no significant differences in the adverse effects in either treatment group. Conclusions: LML therapy is less effective than quadruple therapy as a second-line treatment for H. pylori infection. Therefore, quadruple therapy should be considered as the primary second-line strategy for patients experiencing a failure of first-line H. pylori therapy in Korea.
키워드
Helicobacter pyloriTherapeuticsFailureLevofloxacinMetronidazolePROTON-PUMP INHIBITORRESCUE THERAPYTREATMENT FAILURECONTROLLED-TRIALERADICATIONMETAANALYSISCLARITHROMYCINAMOXICILLINMANAGEMENTRESISTANCE
식별자
- WoS UID
- 000322057500004
- KCI
- ART001789282



로그인
연구물 목록으로